
8 Million
Women will be lost to ovarian cancer by 2050 if we do nothing. (World Ovarian Cancer Coalition 2024)
Join ProSeek Bio to change the status quo
To empower women’s health decisions with new blood tests, starting with ovarian cancer (OC).
Our Vision

Our Solution
To empower women’s health decisions with new blood tests, starting with ovarian cancer (OC).


Our Solution
Clinicians involved in ovarian cancer diagnosis
-
Clinical input
-
Clinical study collaboration
​
Pathology laboratories with mass spectrometry
-
Scientific & regulatory input
-
Partnering for clinical implementation
Women’s health advocates
Input, education & outreach
Our founder designed the innovative LeMBA-MS glycoform biomarker platform technology, previously proven through licensing of esophageal cancer glycoform biomarkers.
A grant from the Ovarian Cancer Research Foundation enabled the discovery and initial validation of new early detection ovarian cancer biomarkers, with commercialization rights assigned to ProSeek Bio.
ProSeek Bio is developing multibiomarker in vitro diagnostic (IVD) kits for use on pathology labs’ clinical mass spectrometers:
OC-Asses Test
test to differentiate ovarian cancer from benign in women presenting with symptoms
OC-Screen Test
test to differentiate ovarian cancer from benign in women presenting with symptoms
